Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.32 |
| ▸ | CES1 | P23141 | 5/20 | 0.31 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28246387 | 0.98 | FAAH (0.31) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL457553 | 0.93 | FAAH (0.36) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL5494627 | 0.90 | FAAH (0.34) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL8181430 | 0.86 | DPP8 (0.32) | FAAH | |
| Trifluoroacetic Acid SCHEMBL4827865 | 0.82 | TSHR (0.33) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL5898930 | 0.82 | FAAH (0.36) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL6950012 | 0.82 | FAAH (0.39) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL4872786 | 0.82 | TSHR (0.37) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL3634014 | 0.82 | ALDH1A1 (0.41) | FAAHCES1MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL19552101 | 0.82 | ALDH1A1 (0.41) | FAAHCES1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304080-B2 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | claimed |
| US-20060148863-A1 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-07-06 | — | — | US | claimed |
| US-20060035943-A1 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-02-16 | — | — | US | claimed |
| US-20050176683-A1 | Hexa-/Tetra-hydro-pyrrolo[1,2-a]imidazole-2,5-dione derivatives; solid phase synthesis | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2005-08-11 | — | — | US | claimed |
| WO-2005056523-A2 | METHODOLOGY FOR PREPARING COMBINATORIAL LIBRARIES BASED UPON A BICYCLIC SCAFFOLD | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-06-23 | — | — | WO | claimed |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. | 2004-10-14 | — | — | US | claimed |
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4101846-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-3889142-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3889142-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3632902-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3549936-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10723716-B2 | Alpha-helix mimetics as modulators of Abeta self-assembly | NEW YORK UNIVERSITY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20040192954-A1 | Protected tyrosine derivatives, method for the production thereof and use of the same for producing o-(2-[18f]-fluoroethyl)-l-tyrosine | FORSCHUNGSZENTRUM GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| US-20040092598-A1 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2004-05-13 | — | — | US | disclosed |
| US-20040023366-A1 | Surface for the immobilization of ligands | DICKOPF STEFAN (DE) | 2004-02-05 | — | — | US | disclosed |
| WO-2004009558-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS, THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASES CAUSED BY SUCH MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| EP-1155002-A4 | METHOD OF SYNTHESIZING BARBITURIC ACID DERIVATIVES AND THEIR USE FOR THE SYNTHESIS OF CHEMICAL LIBRARIES | TRANSTECH PHARMA INC (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-1155002-A1 | METHOD OF SYNTHESIZING BARBITURIC ACID DERIVATIVES AND THEIR USE FOR THE SYNTHESIS OF CHEMICAL LIBRARIES | TransTech Pharma Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000046211-A1 | METHOD OF SYNTHESIZING BARBITURIC ACID DERIVATIVES AND THEIR USE FOR THE SYNTHESIS OF CHEMICAL LIBRARIES | TRANSTECH PHARMA (US) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192954-A1 | Protected tyrosine derivatives, method for the production thereof and use of the same for producing o-(2-[18f]-fluoroethyl)-l-tyrosine | TH, TYR, TYRO3 | FAAH 544/4885CES1 541/4885CES2 381/4885 |
| US-20040092598-A1 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | HDAC1, HDAC11, HDAC3 | FAAH 403/4885CES1 157/4885CES2 875/4885 |
| US-20050176683-A1 | Hexa-/Tetra-hydro-pyrrolo[1,2-a]imidazole-2,5-dione derivatives; solid phase synthesis | ADH1A, ADH1C, ADH5 | FAAH 2637/4885CES1 3926/4885CES2 3565/4885 |
| US-10723716-B2 | Alpha-helix mimetics as modulators of Abeta self-assembly | APP, IAPP, BACE1 | FAAH 704/4885CES1 3316/4885CES2 4418/4885 |
| US-20060035943-A1 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | UPF1, PABPC1, PABPC4 | FAAH 3661/4885CES1 1755/4885CES2 3272/4885 |
| US-20060148863-A1 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | UPF1, PABPC1, PABPC4 | FAAH 3718/4885CES1 1687/4885CES2 3848/4885 |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | UPF1, PABPC1, PABPC4 | FAAH 4299/4885CES1 2865/4885CES2 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.